

Figure 1. Flow cytometer readouts from a control subject, preAD subject and AD patient.




Figure 2. Relative and age-corrected relative lengthening of the G1 phase under the influence of Rapamicin.




Figure 3. Effects of 24 hours rapamicin treatment on cell survival.




Figure 4. Effects of doxorubicine treatment on cell survival



Figure 5. Effects of H_2O_2 treatment on cell survival.

Figure 6. PCR-SSCP analysis for p21 exon2, p57 exon 2 fragments 2A and 2B




Figure 7. Relationship between p21 variants A and B and cyclin expression in the brain.




Figure 8. Relationship between p57 exon 2A variants A and B and cyclin expression in the brain in patients with normal p21 (allele B).




Figure 9. The prevalence of somatic mutations in relation to AD progression and cell cycle proteins in the brain.

